Oura lands $900m Series E, valuation jumps to $11bn

Oura has closed a Series E round of more than $900m, taking the Finnish wearable maker's valuation to $11bn. Fidelity Management & Research Company led the round, with new backer ICONIQ joining alongside returning investors Whale Rock and Atreides.

The raise lands less than a year after Oura closed a $200m round led by Fidelity and Dexcom that valued the company at $5.2bn. That means Oura's valuation has more than doubled in under twelve months, a pace that puts it among the best-funded consumer hardware companies to come out of Europe. The company has now raised roughly $1.5bn since it was founded in Oulu in 2013.

Why investors are still piling in

Oura's pitch to backers rests on sales momentum rather than just a popular gadget. The company says it has sold more than 5.5 million rings since the product launched in 2015, up from 2.5 million as of June 2024 — a doubling in little over a year. Revenue passed $500m in 2024, more than double the prior year, and the company says it expects to reach $1bn in sales in 2025.

Those figures explain why a traditionally conservative asset manager such as Fidelity is leading a second consecutive round. Oura has shifted the smart ring from a niche sleep tracker into a device that increasingly competes with general-purpose wearables from Apple and Samsung, as well as rival ring makers Samsung and RingConn and fitness-focused competitors Whoop and Garmin.

CEO Tom Hale, who took over in 2022 after roles at HomeAway and Linden Lab, framed the new capital around three priorities. "With this investment, we will accelerate innovation, expand our global reach, and set a new standard for what wearables can achieve in advancing preventive health," he said in a statement.

Betting on health data, not just rings

Oura's recent product moves show where that money is likely to go. The company has added Health Panels, a blood-testing feature that lets users schedule lab work and view results for up to 50 biomarkers inside its app, alongside an AI-powered Advisor that turns biometric and lab data into diet and activity suggestions. It also struck a partnership with glucose-monitoring company Dexcom last year to fold continuous glucose data into its app.

That direction points to a company trying to position itself as a hub for preventive health rather than a one-off fitness accessory, competing not just on hardware but on the data services wrapped around it. Hale described the ambition in similar terms, saying Oura wants to build "not just a product, but a global movement toward proactive health — helping people understand their bodies, make better lifestyle decisions, and connect more effectively with their healthcare providers."

The company also launched a ceramic version of its Ring 4 and was named No. 23 on a well-known US ranking of fast-growing disruptors this year, signalling that its growth story is resonating beyond its existing user base of 5.5 million.

What it means for European wearables

For European founders, Oura's trajectory is a rare example of a hardware company built outside Silicon Valley reaching an $11bn valuation without relocating its engineering roots from Finland. It also shows how far a single health-tracking form factor can stretch once a company layers software, lab testing and AI features on top.

The open question is how Oura converts that valuation into durable revenue once rivals such as Samsung and RingConn chase the same market with cheaper hardware. With $1bn in annual sales now in sight and a war chest approaching $1.5bn raised to date, Oura's next test will be proving the AI and health-data features it just funded can keep users paying beyond the initial purchase of a ring.